{"id":23584,"date":"2024-04-09T15:38:30","date_gmt":"2024-04-09T13:38:30","guid":{"rendered":"https:\/\/ggba.swiss\/addex-therapeutics-launches-spin-off-neurosterix-in-geneva-with-usd-63-million-investment\/"},"modified":"2024-04-09T15:41:11","modified_gmt":"2024-04-09T13:41:11","slug":"addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/","title":{"rendered":"Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve avec un investissement de USD 63 millions"},"content":{"rendered":"\n<p>La soci\u00e9t\u00e9 genevoise <a href=\"https:\/\/www.addextherapeutics.com\/en\/\">Addex Therapeutics<\/a>, pionni\u00e8re dans le d\u00e9veloppement de modulateurs allost\u00e9riques pour les troubles neurologiques, a annonc\u00e9 la cr\u00e9ation de <a href=\"https:\/\/www.neurosterix.com\/\">Neurosterix SA<\/a> en collaboration avec des fonds affili\u00e9s \u00e0 Perceptive Advisors, une soci\u00e9t\u00e9 de gestion d&rsquo;investissements ax\u00e9e sur les sciences de la vie. Le lancement est soutenu par un financement initial important de USD 63 millions, destin\u00e9 \u00e0 l&rsquo;acquisition d&rsquo;un portefeuille d&rsquo;actifs neuroscientifiques pr\u00e9cliniques et d&rsquo;une plateforme technologique de pointe pour la d\u00e9couverte de m\u00e9dicaments modulateurs allost\u00e9riques aupr\u00e8s d&rsquo;Addex.<\/p>\n\n\n\n<p>Neurosterix, \u00e9galement bas\u00e9e \u00e0 Gen\u00e8ve, entend acc\u00e9l\u00e9rer le d\u00e9veloppement de ces actifs, en s&rsquo;appuyant sur l&rsquo;investissement substantiel de <a href=\"https:\/\/xontogeny.com\/portfolio\/\">Perceptive Xontogeny Venture Fund II<\/a>, ainsi que sur les contributions de <a href=\"https:\/\/www.perceptivelife.com\/life-sciences\/\">Perceptive Life Sciences Fund<\/a> et d&rsquo;<a href=\"http:\/\/www.acornbioventures.com\/\">Acorn Bioventures<\/a>. Ce mouvement strat\u00e9gique permet \u00e0 Addex de maintenir ses partenariats en cours avec Janssen Pharmaceuticals, Inc. et Indivior PLC, et de continuer \u00e0 faire avancer ses projets en phase clinique, y compris les th\u00e9rapies pour la maladie de Parkinson et la toux chronique, tout en conservant une participation significative dans Neurosterix.<\/p>\n\n\n\n<p>L&rsquo;accord financier entre Addex et Neurosterix permet non seulement \u00e0 Addex d&rsquo;obtenir CHF 5 millions en liquidit\u00e9s, mais aussi de prendre une participation de 20 % dans Neurosterix. Cette collaboration souligne la valeur de la plateforme technologique d&rsquo;Addex et a pour but de r\u00e9duire les co\u00fbts d&rsquo;exploitation d&rsquo;Addex, d&rsquo;\u00e9tendre sa marge de man\u0153uvre financi\u00e8re et de lui permettre de continuer \u00e0 se concentrer sur l&rsquo;atteinte d&rsquo;\u00e9tapes cl\u00e9s dans ses programmes en partenariat.<\/p>\n\n\n\n<p>Tim Dyer, CEO d&rsquo;Addex, aura la double casquette de CEO de Neurosterix, guidant la jeune soci\u00e9t\u00e9 dans sa mission d&rsquo;apporter de nouveaux traitements \u00e0 la clinique. Ce changement entra\u00eene un remaniement au sein de la direction d&rsquo;Addex, des personnalit\u00e9s importantes se retirant pour consacrer leur expertise \u00e0 Neurosterix, tout en continuant \u00e0 soutenir Addex par le biais d&rsquo;un accord de service.<\/p>\n\n\n\n<p>Cette collaboration t\u00e9moigne du potentiel reconnu de la technologie des modulateurs allost\u00e9riques dans le domaine de la d\u00e9couverte de m\u00e9dicaments, connue pour sa s\u00e9lectivit\u00e9 et sa pr\u00e9cision dans sa capacit\u00e9 \u00e0 influencer les m\u00e9canismes biologiques. Soutenue par Perceptive Advisors, Neurosterix est bien positionn\u00e9e pour acc\u00e9l\u00e9rer le d\u00e9veloppement de ses actifs pr\u00e9cliniques pour apporter des contributions significatives au traitement des troubles neurologiques.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La soci\u00e9t\u00e9 genevoise Addex Therapeutics s&rsquo;est associ\u00e9e \u00e0 Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le d\u00e9veloppement de m\u00e9dicaments ax\u00e9s sur la neurologie.<\/p>\n","protected":false},"author":6,"featured_media":23581,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1244,1148,1188,1239,1141,1171],"class_list":["post-23584","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-company-creation-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-neuroscience-fr-2","tag-personalized-medicine-fr-2","tag-pharma-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve | GGBa<\/title>\n<meta name=\"description\" content=\"La soci\u00e9t\u00e9 genevoise Addex Therapeutics s&#039;est associ\u00e9e \u00e0 Perceptive Advisors pour lancer la spin-off Neurosterix.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve | GGBa\" \/>\n<meta property=\"og:description\" content=\"La soci\u00e9t\u00e9 genevoise Addex Therapeutics s&#039;est associ\u00e9e \u00e0 Perceptive Advisors pour lancer la spin-off Neurosterix.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-09T13:38:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-09T13:41:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Neurosterix_Addex_1180x811.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve avec un investissement de USD 63 millions\",\"datePublished\":\"2024-04-09T13:38:30+00:00\",\"dateModified\":\"2024-04-09T13:41:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/\"},\"wordCount\":422,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Neurosterix_Addex_1180x811.jpeg\",\"keywords\":[\"Biotech\",\"Company Creation\",\"Financing\",\"Healthcare\",\"Neuroscience\",\"Personalized Medicine\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/\",\"name\":\"Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Neurosterix_Addex_1180x811.jpeg\",\"datePublished\":\"2024-04-09T13:38:30+00:00\",\"dateModified\":\"2024-04-09T13:41:11+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"La soci\u00e9t\u00e9 genevoise Addex Therapeutics s'est associ\u00e9e \u00e0 Perceptive Advisors pour lancer la spin-off Neurosterix.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Neurosterix_Addex_1180x811.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Neurosterix_Addex_1180x811.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Neurosterix est une soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de modulateurs allost\u00e9riques pour le traitement des troubles neurologiques. | \u00a9 Neurosterix\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve avec un investissement de USD 63 millions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve | GGBa","description":"La soci\u00e9t\u00e9 genevoise Addex Therapeutics s'est associ\u00e9e \u00e0 Perceptive Advisors pour lancer la spin-off Neurosterix.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/","og_locale":"fr_FR","og_type":"article","og_title":"Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve | GGBa","og_description":"La soci\u00e9t\u00e9 genevoise Addex Therapeutics s'est associ\u00e9e \u00e0 Perceptive Advisors pour lancer la spin-off Neurosterix.","og_url":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-04-09T13:38:30+00:00","article_modified_time":"2024-04-09T13:41:11+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Neurosterix_Addex_1180x811.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve avec un investissement de USD 63 millions","datePublished":"2024-04-09T13:38:30+00:00","dateModified":"2024-04-09T13:41:11+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/"},"wordCount":422,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Neurosterix_Addex_1180x811.jpeg","keywords":["Biotech","Company Creation","Financing","Healthcare","Neuroscience","Personalized Medicine","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/","url":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/","name":"Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Neurosterix_Addex_1180x811.jpeg","datePublished":"2024-04-09T13:38:30+00:00","dateModified":"2024-04-09T13:41:11+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"La soci\u00e9t\u00e9 genevoise Addex Therapeutics s'est associ\u00e9e \u00e0 Perceptive Advisors pour lancer la spin-off Neurosterix.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Neurosterix_Addex_1180x811.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/04\/Neurosterix_Addex_1180x811.jpeg","width":1180,"height":811,"caption":"Neurosterix est une soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de modulateurs allost\u00e9riques pour le traitement des troubles neurologiques. | \u00a9 Neurosterix"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Addex Therapeutics lance la spin-off Neurosterix \u00e0 Gen\u00e8ve avec un investissement de USD 63 millions"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/23584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=23584"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/23584\/revisions"}],"predecessor-version":[{"id":23586,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/23584\/revisions\/23586"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/23581"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=23584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=23584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=23584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}